BARDA Releases 2022-26 Strategic Plan

May 25, 2022

This week, Biomedical Advanced Research and Development Authority (BARDA) director Gary Disbrow, PhD, issued the 2022-26 BARDA Strategic Plan, which outlines the agency’s plan to further secure the nation during public health emergencies.

The plan is built around four strategic goals:

  • Enhance preparedness against health security threats and invest in technology that will improve the national portfolio of medical countermeasures (MCMs).
  • Strengthen BARDA’s response posture to improve its capacity to support public health emergency response efforts.
  • Develop and nurture partnerships with the private sector to advance optimal MCM solutions to mitigate health security.
  • Expand, maintain and support a world-class workforce to serve the country’s critical needs.

Each goal is supported by critical objectives. Of particular interest to the AABB community, BARDA will launch new efforts to address emerging infectious diseases and prioritize strategies to develop proven technologies for vaccines, therapeutics and diagnostics.

As part of its effort to promote interventions across the continuum of care, BARDA will also engage with stakeholders to inform MCM development to treat trauma and radiation injuries (including next-generation blood products) from nuclear threats.

The report also includes a summary of the agency’s COVID-19 response efforts and an overview of key legislation. AABB encourages members to view the entire strategic plan.